• Home
  • American Society of Clinical Oncology Annual Meeting 2026

ASCO 2026


Chicago, IL

American Society of Clinical Oncology Annual Meeting 2026
Explore more Oncology congress materials
Material Type

Results(12)

Oncology
Molecular circulating tumor DNA profiling from patients treated with zanidatamab + chemotherapy in first-line HER2-positive advanced or metastatic gastroesophageal adenocarcinoma
Author(s): Elena Elimova, Geoffery Ku, Keun-Wook Lee et al.
Characterization and Management of Gastrointestinal Adverse Events With Zanidatamab + Chemotherapy ±Tislelizumab in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma: Analysis From HERIZON-GEA-01
Author(s): Elena Elimova, Sun Young Rha, Kohei Shitara et al.
Zanidatamab + chemotherapy ± tislelizumab for ​ first-line HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma: ​ PD-L1 subgroup analysis from HERIZON-GEA-01​
Author(s): Sun Young Rha, Kohei Shitara, Lin Shen et al.